Pfizer Charts Big Course for PF’4404 Bispecific Antibody in Cancer Development

Pfizer Inc. (PFE) is ramping up the clinical development of its investigational bispecific antibody PF’4404 (also known as SSGJ‑707 / PF‑08634404), targeting both PD‑1 and VEGF. The company unveiled a three‑pronged strategy centered on speed, breadth and scientific rigor: launching seven near‑term clinical trials, covering multiple tumour types such as lung and colorectal cancers, and positioning PF’4404 to become a backbone agent across lines of therapy. What sets this approach apart: in the first‑line non‑small‑cell lung cancer (NSCLC) setting, Pfizer is directly comparing PF’4404 plus chemotherapy against the current standard of care (anti‑PD‑1 plus chemo). Meanwhile, in metastatic colorectal cancer (mCRC) the company has initiated a Phase 3 trial contrasting PF’4404 plus chemo versus bevacizumab plus chemo in microsatellite‑stable patients. The framework builds on Pfizer’s recent licensing agreement with 3SBio, Inc., giving the company global (ex‑China) rights to develop and commercialise PF’4404, indicating strong conviction in the program’s potential. Overall, Pfizer is positioning PF’4404 not just as another regimen, but as a possible new backbone immunotherapy‑plus‑angiogenesis combination — an aggressive and bold move in a crowded field. #PfizerOncology #BispecificAntibody #PD1VEGF #CancerTherapy #SlimScan #GrowthStocks #CANSLIM